Moneycontrol PRO
UPCOMING EVENT:Watch leaders discuss the biggest issue of our times at the Sustainability 100+ Summit. Register now!
you are here: HomeNewsTrendsHealth

Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

September 02, 2021 / 07:36 PM IST
Representative image

Representative image

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

"Granules is working closely with DRDO team to launch the product in India at the earliest," it added.

The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said.

Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.
PTI
first published: Sep 2, 2021 07:36 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark